ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2020
Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management.
Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- Non-Opioid Pharmaceutical Alternatives for Acute Pain Management in the Emergency Department: A Scoping Review.The western journal of emergency medicine · 2026Article
- Article
- Suspected Cannabinoid Hyperemesis Syndrome in a Traveler from a Cannabis-Legal Country: A Case Report from Japan.Juntendo medical journal · 2026Article
- Cannabis Hyperemesis Syndrome in Youth: Clinical Insights and Public Health Implications.International journal of environmental research and public health · 2025Review
- A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Adverse Impact of Cannabis on Human Health.Annual review of medicine · 2024Review
- Trends of emergency department visits for cannabinoid hyperemesis syndrome in Nevada: An interrupted time series analysis.PloS one · 2024Article
- Cannabis Hyperemesis Syndrome in a Recently Abstinent Chronic User: Assessment and Intervention.Consortium psychiatricum · 2024Article
- Cannabinoid Hyperemesis Syndrome in a 23-Year-Old Woman with Uncontrolled Type 1 Diabetes Mellitus.The American journal of case reports · 2023Article
- A Case of Cannabinoid Hyperemesis Syndrome and Acute Kidney Injury: A Review of the Literature.Cureus · 2023Article
- Review
- Case report: A case of undiagnosed cannabinoid hyperemesis syndrome in rural part of Nepal.Annals of medicine and surgery (2012) · 2022Article
- Response to 'Fool's gold: diseased marijuana and cannabis hyperemesis syndrome'.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- Fool's gold: diseased marijuana and cannabis hyperemesis syndrome.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.Proceedings (Baylor University. Medical Center) · 2021Article
- Cannabinoid hyperemesis syndrome: the conundrum is here to stay.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although cannabinoid hyperemesis syndrome (CHS) was first reported more than 15 years ago, it still remains an unfamiliar clinical entity among physicians worldwide. CHS is categorized by Rome IV classification as a functional gastroduodenal disorder. It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis. CHS is also associated with abdominal pain reduced by hot baths and showers with comparative well-being between attacks. Thus, its clinical presentation resembles 'classic' cyclic vomiting syndrome, but eliciting a cannabis history is crucial in diagnosing this entity. In acute attacks, parenteral benzodiazepines are very effective. For prevention and long-term management, tricyclic antidepressants such as amitriptyline are the mainstay of therapy requiring doses in the range of 50-200 mg/d to achieve symptom control. In addition, counseling to achieve marijuana cessation, accompanied by antianxiety medications, is necessary for sustaining clinical outcomes. Once the patient is in remission and off marijuana for a period of 6-12 months, then tapering the dose of amitriptyline can be implemented, with the goal of no therapy being achieved in the majority of patients over time. With the legalization of marijuana in many states, CHS will become an increasingly prevalent clinical entity, so educating about CHS is an important goal, particularly for emergency department physicians who generally first encounter these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.